Cargando…

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma (MM), a plasma cell neoplasm, is an incurable hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most common adverse genomic abnormality associated with disease progression and drug resistance. While possible mechanisms of 1q21+ occurr...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hanamura, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827173/ https://www.ncbi.nlm.nih.gov/pubmed/33445467 http://dx.doi.org/10.3390/cancers13020256

Ejemplares similares

Chromosome 1q21 abnormalities in multiple myeloma
por: Schmidt, Timothy M., et al.
Publicado: (2021)

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
por: Tang, Hoi Ki Karen, et al.
Publicado: (2022)

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
por: Barbieri, Emiliano, et al.
Publicado: (2022)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
por: Yu, Wenjun, et al.
Publicado: (2016)

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients
por: Skerget, Matevz, et al.
Publicado: (2023)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Multiple myeloma with high-risk cytogenetics and its treatment approach
por: Hanamura, Ichiro
Publicado: (2022)

Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real‐world analysis
por: Wang, Yu‐tong, et al.
Publicado: (2022)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets
por: Burroughs Garcìa, Jessica, et al.
Publicado: (2021)

Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials
por: Chen, Liang, et al.
Publicado: (2020)

Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma
por: Rao, Pulivarthi H, et al.
Publicado: (2004)

Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal Translocations
por: Hanamura, Ichiro, et al.
Publicado: (2001)

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
por: Teoh, Phaik Ju, et al.
Publicado: (2020)

Amplification of the 20q Chromosomal Arm Occurs Early in Tumorigenic Transformation and May Initiate Cancer
por: Tabach, Yuval, et al.
Publicado: (2011)

A novel human multiple myeloma cell line with a 1q21 gain genetic abnormality and CKS1B overexpression
por: He, Jie, et al.
Publicado: (2023)

ARNT/HIF‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma
por: Wu, Chuan, et al.
Publicado: (2018)

Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer
por: Voutsadakis, Ioannis A.
Publicado: (2021)

Prognostic significance of chromosome arm 1q gain and methylation class in molecularly defined diffuse leptomeningeal glioneuronal tumor
por: Chiang, Jason, et al.
Publicado: (2022)

Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
por: Gao, Wen, et al.
Publicado: (2020)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients
por: Weinhold, Niels, et al.
Publicado: (2021)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

S185: TARGETING DNA2 OVERCOMES METABOLIC REPROGRAMMING IN 1Q21 MULTIPLE MYELOMA
por: Thongon, Natthakan, et al.
Publicado: (2023)

Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma
por: Kim, Miyoung, et al.
Publicado: (2016)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

Mapping of the chromosomal amplification 1p21-22 in bladder cancer
por: Scaravilli, Mauro, et al.
Publicado: (2014)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma
por: Johnson, Travis S., et al.
Publicado: (2023)

Chromosomal instability and acquired drug resistance in multiple myeloma
por: Wang, Wang, et al.
Publicado: (2017)

Association studies between chromosomal regions 1q21.3, 5q21.3, 14q21.2 and 17q21.31 and numbers of children in Poland
por: Clark, Jeremy S. C., et al.
Publicado: (2022)

Loss of chromosome 11q21–23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma
por: Stokke, T, et al.
Publicado: (2001)

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
por: Chatonnet, Fabrice, et al.
Publicado: (2020)

Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24
por: Abel, F, et al.
Publicado: (1999)

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers
por: Lamy, Pierre-Jean, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v1ti5804pgitdrb1a97ir7v44m